Arkolith/Insider Trading/LYEL/Form 4

Meltz Mark A

General CounselLyell Immunopharma, Inc. (LYEL) · full profile →Form 4 · filed Feb 11, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
0 non-derivative · 1 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 10, 2026Grant(A)50K—$050K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001771329-26-000001) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML